银屑病性关节炎免疫机制及生物制剂治疗的进展  

Psoriatic arthritis： immunologic mechanisms and biological therapy

作　　者：赵伟[1,2] 龚瑜[1] 史玉玲[1] 

机构地区：[1]同济大学附属第十人民医院皮肤科,上海200072 [2]上海市皮肤病医院

出　　处：《国际皮肤性病学杂志》2015年第5期290-293,共4页International Journal of Dermatology and Venereology

基　　金：国家自然科学基金（81301356）;上海市自然科学基金（13ZR1432200）;上海市科学技术委员会引导项目（134119b0700）

摘　　要：银屑病性关节炎是一种与银屑病相关的炎症性关节病,病程迁延反复,晚期可致关节强直甚至致残,严重影响患者的生活质量.因此,早期诊断,早期干预以及制定有效的治疗方案改善患者的关节症状,缓解其心身的双重压力是银屑病性关节炎面临的挑战.银屑病性关节炎的发病机制十分复杂,有多种免疫细胞和免疫分子参与,异常T细胞的活化、增殖、分化是发病的主要原因.此外,肿瘤坏死因子α和白细胞介素12、23、17等为主要的炎症介质靶点.针对发病机制中不同炎症因子的靶向治疗药物,为银屑病性关节炎的治疗带来了革命性的变化.目前,一些新型的生物靶向药物正在研究中,有希望成为银屑病性关节炎患者未来治疗的新选择.Psoriatic arthritis （PsA）,a psoriasis-associated inflammatory arthropathy with a chronic and recurrent clinical course,may lead to ankylosis and even disability at late stage,and seriously affects the quality of life in patients.It remains a challenge to improve joint symptoms and relieve physical and mental stress by early diagnosis,early intervention and effective therapeutic strategies.The pathogenesis of PsA is very complicated with the involvement of various immunocytes and immune molecules,in which the abnormal activation,proliferation and differentiation of T-lymphocytes may play a key role.Additionally,tumor necrosis factor alpha （TNF-α）,interleukin 12 （IL-12）,IL-23 and IL-17 are the main targets for inflammatory mediators.Aiming directly at different inflammatory cytokines in the pathogenesis of PsA,targeted drugs have brought revolutionary changes for the treatment of PsA.At present,some novel targeted biological drugs are under investigation,and may bring novel choices for the treatment of PsA.

关 键 词：银屑病性关节炎 免疫 靶向治疗 生物制剂 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]